Artivion, Inc. (NYSE: AORT) has completed its acquisition of Endospan Ltd., developer of the FDA-approved NEXUS Aortic Arch System, after announcing on May 8 that it would exercise its option to acquire the company. The transaction includes an upfront net purchase price of approximately $131.3 million, funded through Artivion’s previously drawn $150 million delayed draw term loan, along with up to $200 million in additional milestone payments tied to commercial performance over the next two years.

The FDA approved the NEXUS branched endovascular stent graft system in April 2026. Artivion has served as the exclusive distributor of the device across Europe, the Middle East, and Africa since 2019. The company estimates NEXUS addresses an annual U.S. market opportunity of approximately $150 million.

The acquisition expands Artivion’s aortic arch portfolio alongside its AMDS hybrid prosthesis and ARCEVO LSA hybrid stent graft system, positioning the company as the only provider with a complete portfolio of aortic arch solutions. CEO Pat Mackin said NEXUS represents a platform technology rather than a single-device acquisition and adds a pipeline of next-generation arch technologies currently in development.

Strategically, the deal strengthens Artivion’s position in the growing endovascular aortic repair market by expanding its minimally invasive treatment offerings and reinforcing its leadership in complex aortic arch repair. Potential benefits include growth in the company’s endovascular segment and broader adoption in cardiovascular surgery centers, while risks include integration execution, commercialization challenges, acquisition-related debt, and the pace of U.S. market adoption.